Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 4/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 5/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.42 |
| ▸ | CDK7 | P50613 | 3/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.42 |
| ▸ | CCNK | O75909 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | CCNH | P51946 | 2/20 | 0.42 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.42 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.41 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931173 | 0.97 | BCL6 (0.48) | BCL6NTRK1CDK9CDK2CDK7 | |
| SCHEMBL11931177 | 0.97 | BCL6 (0.48) | BCL6NTRK1CDK9CDK2CDK7 | |
| SCHEMBL11931180 | 0.94 | CDK9 (0.49) | BCL6NTRK1CDK9CDK2CDK7 | |
| SCHEMBL14395171 | 0.86 | CDK9 (0.49) | BCL6NTRK1CDK9CDK2CDK7 | |
| SCHEMBL14395116 | 0.86 | NTRK1 (0.46) | NTRK1HDAC1SYKNPC1RAB9A | |
| SCHEMBL11931184 | 0.80 | HDAC1 (0.40) | IRAK4HDAC1ALDH1A1MAP3K5CRACR2A | |
| SCHEMBL11931181 | 0.80 | HDAC1 (0.40) | IRAK4HDAC1ALDH1A1MAP3K5CRACR2A | |
| SCHEMBL11931171 | 0.80 | MAP3K5 (0.45) | CDK2GSK3BCCNA2HDAC1ALDH1A1 | |
| SCHEMBL11931172 | 0.79 | ALDH1A1 (0.45) | CDK2GSK3BCCNA2HDAC1NPC1 | |
| SCHEMBL14395351 | 0.79 | HDAC1 (0.46) | HDAC1NPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-7511049-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511049-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7309705-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309705-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070275983-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070275983-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| EP-1534710-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007044441-A2 | USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275983-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CDKN1A | BCL6 985/4885NTRK1 3181/4885CDK9 9/4885 |
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | BCL6 1167/4885NTRK1 1561/4885CDK9 117/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | BCL6 1167/4885NTRK1 1561/4885CDK9 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.